CareDx Shareholder Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In CareDx To Contact Him Directly To Discuss Their Options

November 05, 2021 6:26 PM EDT | Source: Faruqi & Faruqi LLP

New York, New York--(Newsfile Corp. - November 5, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).

If you suffered losses exceeding $50,000 investing in CareDx stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CDNA.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6455/102263_1678787d046aa87f_001.jpg


There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

On October 28, 2021, in its 10-Q filing, CareDx disclosed that the Department of Justice ("DOJ") issued a civil investigative demand ("CID") "requesting that the Company produce certain documents in connection with a False Claims Act investigation being conducted by the DOJ regarding certain business practices related to our kidney testing and phlebotomy services, and a subpoena from the United States Securities and Exchange Commission (SEC) in relation to an investigation by the SEC in respect of matters similar to those identified in the CID, as well as certain of our accounting and public reporting practices." On this news, the price of the Company's stock declined.

On this news the stock dropped as low as $50.53, a 28% drop from the previous day's closing price.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102263

info